Global Health and Population Project on Access to Care for Cardiometabolic Diseases (HPACC)


About HPACC

Global Health and Population Project on Access to Care for Cardiometabolic Diseases (HPACC) is an international research consortium and was established to meet the clear need for answers to key health policy and clinical questions relating to cardiometabolic diseases globally. We search, obtain and harmonize nationally representative survey data on cardiometabolic diseases with a focus on low- and middle-income countries (LMICs) to close existing research gaps. Our goal is to become a global center of excellence for data sharing and analysis related to cardiometabolic diseases.

HPACC currently consists of nationally representative, population-based surveys from 76 countries across 6 world regions. HPACC has individual-level data of over 1.2 million adults. Surveys were conducted from 2005 to 2019 and most surveys are WHO STEPS or DHS surveys. More information can be found at https://www.hpaccproject.org/.

Collaborators

HPACC is a collaboration of more than 80 physicians, economists, and public health researchers from more than 30 countries. The leadership team comes from Harvard University, Stanford University, the University of Göttingen, Heidelberg University, the University of Birmingham, and the University of Edinburgh.

Funders

HPACC is proudly supported by the Harvard McLennan Family Fund, Alexander von Humboldt Foundation, Michigan Center for Diabetes Translational Research, and institutional funds from the Heidelberg Universities and Universities of Göttingen.

Featured scientific papers

Patterns of tobacco use in low and middle income countries by tobacco product and sociodemographic characteristics: nationally representative survey data from 82 countries.

Author(s): Theilmann M, Lemp JM, Winkler V, Manne-Goehler J, Marcus ME, Probst C, Lopez-Arboleda WA, Ebert C, Bommer C, Mathur M, Andall-Brereton G, Bahendeka SK, Bovet P, Farzadfar F, Ghasemi E, Mayige MT, Saeedi Moghaddam S, Mwangi KJ, Naderimagham S, Sturua L, Atun R, Davies JI, Bärnighausen T, Vollmer S, Geldsetzer PJournal: BMJPMID: 36041745 August 2022
To determine the prevalence and frequency of using any tobacco product and each of a detailed set of tobacco products,…

Rural-Urban Differences in Diabetes Care and Control in 42 Low- and Middle-Income Countries: A Cross-sectional Study of Nationally Representative Individual-Level Data.

Author(s): Flood D, Geldsetzer P, Agoudavi K, Aryal KK, Brant LCC, Brian G, Dorobantu M, Farzadfar F, Gheorghe-Fronea O, Gurung MS, Guwatudde D, Houehanou C, Jorgensen JMA, Kondal D, Labadarios D, Marcus ME, Mayige M, Moghimi M, Norov B, Perman G, Quesnel-Crooks S, Rashidi MM, Moghaddam SS, Seiglie JA, Karaireho SKB, Steinbrook E, Theilmann M, Ware LJ, Vollmer S, Atun R, Davies JI, Ali MK, Rohloff P, Manne-Goehler JJournal: Diabetes CarePMID: 35771765 June 2022
Diabetes prevalence is increasing rapidly in rural areas of low- and middle-income countries (LMICs), but there are limited data on…

Data Resource Profile: The Global Health and Population Project on Access to Care for Cardiometabolic Diseases (HPACC).

Author(s): Manne-Goehler J, Theilmann M, Flood D, Marcus ME, Andall-Brereton G, Agoudavi K, Arboleda WAL, Aryal KK, Bicaba B, Bovet P, Brant LCC, Brian G, Chamberlin G, Chen G, Damasceno A, Dorobantu M, Dunn M, Ebert C, Farzadfar F, Gurung MS, Guwatudde D, Houehanou C, Houinato D, Hwalla N, Jorgensen JMA, Karki KB, Labadarios D, Lunet N, Malta DC, Martins JS, Mayige MT, McClure RW, Saeedi Moghaddam S, Mwangi KJ, Mwalim O, Norov B, Quesnel-Crooks S, Rhode S, Seiglie JA, Sibai A, Silver BK, Sturua L, Stokes A, Supiyev A, Tsabedze L, Zhumadilov Z, Jaacks LM, Atun R, Davies JI, Geldsetzer P, Vollmer S, Bärnighausen TWJournal: Int J EpidemiolPMID: 35762972 June 2022

Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data.

Author(s): Marcus ME, Manne-Goehler J, Theilmann M, Farzadfar F, Moghaddam SS, Keykhaei M, Hajebi A, Tschida S, Lemp JM, Aryal KK, Dunn M, Houehanou C, Bahendeka S, Rohloff P, Atun R, Bärnighausen TW, Geldsetzer P, Ramirez-Zea M, Chopra V, Heisler M, Davies JI, Huffman MD, Vollmer S, Flood DJournal: Lancet Glob HealthPMID: 35180420 March 2022
In the prevention of cardiovascular disease, a WHO target is that at least 50% of eligible people use statins. Robust…